These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26268329)

  • 1. Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase.
    Tan Y; Zhang Q; Wong SG; Hua Q
    Curr Top Med Chem; 2016; 16(5):549-57. PubMed ID: 26268329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of gamma-secretase inhibitors and modulators.
    Imbimbo BP
    Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
    Crump CJ; Johnson DS; Li YM
    Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in gamma-secretase modulation.
    Pissarnitski D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
    McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
    J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
    Imbimbo BP; Giardina GA
    Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γ-Secretase and its modulators: Twenty years and beyond.
    Xia W
    Neurosci Lett; 2019 May; 701():162-169. PubMed ID: 30763650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γ-Secretase inhibitors and modulators.
    Golde TE; Koo EH; Felsenstein KM; Osborne BA; Miele L
    Biochim Biophys Acta; 2013 Dec; 1828(12):2898-907. PubMed ID: 23791707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
    Czirr E; Weggen S
    Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
    Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
    Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition and modulation of gamma-secretase for Alzheimer's disease.
    Wolfe MS
    Neurotherapeutics; 2008 Jul; 5(3):391-8. PubMed ID: 18625450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of presenilin 1-selective γ-secretase inhibitors with reconstituted γ-secretase complexes.
    Lee J; Song L; Terracina G; Bara T; Josien H; Asberom T; Sasikumar TK; Burnett DA; Clader J; Parker EM; Zhang L
    Biochemistry; 2011 Jun; 50(22):4973-80. PubMed ID: 21528914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presenilin is the molecular target of acidic γ-secretase modulators in living cells.
    Jumpertz T; Rennhack A; Ness J; Baches S; Pietrzik CU; Bulic B; Weggen S
    PLoS One; 2012; 7(1):e30484. PubMed ID: 22238696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.